Skip to main content

Advertisement

Table 2 Published or presented studies with results in NSCLC patients treated with targeted agents beyond EGFR-TKIs

From: Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

Target Agent Phase Eligibility Number of patients ORR (%) PFS (months) OS (months) References
ALK Crizotinib III Pretreated, ALK-rearranged 347 65 7.7 20.3 [53]
Crizotinib III Untreated, ALK-rearranged 343 74 10.9 NR [54]
Ceritinib I Pretreated, ALK-rearranged 114 (at least 400 mg) 58 (overall population) 7.0 NR [56]
56 (crizotinib-treated) 6.9
62 (crizotinib-naive) 10.4
Alectinib I–II ALK-rearranged 46 93.5 NR NR [58]
ALK inhibitor-naive
Alectinib I–II ALK-rearranged, crizotinib-resistant 47 55 NR NR [60]
ROS1 Crizotinib I ROS1-rearranged 50 72 19.2 NR [61]
MET Crizotinib I MET-amplified 13 20 (intermediate amplification) NR NR [62]
50 (high amplification)
BRAF Dabrafenib II BRAF V600E mutation-positive 17 54 NR NR [63]
HER2 Anti-HER2 agents Retrospective HER2 mutation-positive 16 50 5.1 NR [64]
FGFR1 BGJ398 I FGFR1-amplified 17 11.7 NR NR [65]
  1. ALK anaplastic lymphoma kinase, ROS1 c-ros oncogene 1, MET proto-oncogene protein c-met, BRAF v-Raf murine sarcoma viral oncogene homolog B1, HER2 human epidermal growth factor receptor 2, FGFR1 fibroblast growth factor receptor 1, ORR objective response rate, NR not reported or not reached. Other abbreviations as in Table 1.